Q: What is Yeztugo used for?

Yeztugo is used to treat paroxysmal nocturnal hemoglobinuria .

Q: How does Yeztugo work?

Mechanism of Action Yeztugo belongs to a class of medications called capsid inhibitors. It works differently than many other HIV treatments by targeting the HIV-1 capsid, which is the protein shell that surrounds and protects the virus's genetic material and the enzymes it needs to multiply. The medication interferes with the viral life cycle at several distinct stages: Nuclear Entry: It prevents the virus from transporting its genetic material into the nucleus of the host cell, a step required for the virus to integrate into the cell's DNA. Virus Assembly: It disrupts the process of building new virus particles inside the infected cell. Capsid Maturation: It interferes with the formation of the capsid shell in new viruses, resulting in virus particles that are defective and unable to infect other cells. By blocking these multiple steps, Yeztugo helps lower the amount of HIV in the blood, known as the viral load. Because it uses a unique mechanism to attack the virus, it is particularly useful for individuals whose HIV has developed resistance to other classes of antiretroviral drugs.

Q: What are the active ingredients in Yeztugo?

The active ingredient in Yeztugo is lenacapavir .

Q: What are the side effects of Yeztugo?

Common Side Effects The most frequently reported side effects of Yeztugo involve reactions where the medication is injected. These symptoms are usually mild to moderate but can last for an extended period. Common side effects include: Injection site reactions: Pain, redness, swelling, itching, or a burning sensation at the site of the injection. Nodules and induration: Small lumps or hardened areas under the skin at the injection site. These lumps are common and may remain visible or felt for several months. Nausea: Feeling sick to the stomach. Serious Side Effects In some cases, Yeztugo can cause more severe reactions. You should contact your healthcare provider immediately if you experience any of the following: Severe injection site reactions: Signs of a skin infection, such as pus, drainage, extreme warmth, or ulcers at the site where the medicine was given. Allergic reactions: Symptoms such as a severe skin rash, hives, swelling of the face, lips, or tongue, or difficulty breathing. Immune system changes: A condition called Immune Reconstitution Inflammatory Syndrome (IRIS) can occur, where the immune system reacts strongly to previously hidden infections. This is more common in individuals with a history of advanced HIV infection. This is not a complete list of all possible side effects. If you notice other symptoms or if your injection site reactions become bothersome or do not improve, consult your doctor or pharmacist. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Yeztugo?

Yeztugo belongs to the CGRP antagonist drug class.

Q: What is the dosage of Yeztugo and how do I take it?

How Yeztugo is Administered Yeztugo treatment typically begins with a starting phase that includes oral tablets. These tablets are taken by mouth, with or without food, for a short period as directed by a healthcare provider. Following the initial oral doses, the medication is transitioned to long-acting injections. These injections are administered by a healthcare professional under the skin, usually in the abdomen. Maintenance Schedule Once the maintenance phase begins, Yeztugo is usually given as an injection once every six months. It is important to attend all scheduled appointments to ensure the medication remains effective. Missed Doses If you miss an appointment for an injection or forget to take the oral tablets during the starting phase, contact your healthcare provider right away for guidance. Consistent dosing is necessary to maintain the effectiveness of the treatment.

Q: Is Yeztugo safe during pregnancy and breastfeeding?

Pregnancy There is currently not enough research to determine if Yeztugo is safe to use during pregnancy. It is unknown whether the medication can cause harm to a developing fetus. If you are pregnant or planning to become pregnant, your healthcare provider will help you weigh the benefits of the medication against any potential risks. Breastfeeding It is not known if Yeztugo passes into breast milk or if it could affect a nursing child. For individuals with HIV, the standard recommendation is to avoid breastfeeding to prevent transmitting the virus to the infant. If you are taking Yeztugo for HIV prevention, talk to your doctor about whether it is safe to breastfeed while receiving this treatment.

Q: What is the FDA approval status of Yeztugo?

FDA Approval Status The U.S. Food and Drug Administration (FDA) approved Yeztugo (emtricitabine and tenofovir alafenamide) on September 23, 2024. It is the first generic version of Descovy to receive FDA approval. Approved Indications Yeztugo is approved for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg (77 lbs). It is intended for individuals who are at risk of HIV and have a confirmed negative HIV-1 test result immediately prior to starting the medication. Boxed Warnings The FDA-approved labeling for Yeztugo includes a boxed warning, the most serious type of warning, for the following risks: HIV-1 Resistance: Yeztugo must only be used by individuals confirmed to be HIV-negative. If the medication is taken by someone with an undiagnosed HIV-1 infection, it may lead to the development of drug-resistant HIV-1 strains, making the infection harder to treat. Hepatitis B Exacerbation: Severe, acute flare-ups of hepatitis B virus (HBV) infection have been reported in patients who have both HIV-1 and HBV and stop taking medications containing emtricitabine or tenofovir. Patients with HBV should be closely monitored by a healthcare provider for several months after stopping Yeztugo. Regulatory Requirements To ensure safety and effectiveness, the FDA requires that healthcare providers verify an individual's HIV-negative status before prescribing Yeztugo and at least every three months during treatment. This frequent testing is necessary to prevent the use of PrEP in someone who has acquired HIV-1, which could lead to drug resistance.

Question 1

What is Yeztugo?

Accepted Answer

Yeztugo is a medication used to help lower cholesterol levels in the blood. It is typically associated with conditions such as high cholesterol and certain types of hyperlipidemia. By reducing cholesterol, it may help decrease the risk of cardiovascular problems. Yeztugo is part of a class of drugs that target cholesterol absorption or production in the body.

Question 2

What is Yeztugo used for?

Accepted Answer

Yeztugo is used to treat paroxysmal nocturnal hemoglobinuria.

Question 3

How does Yeztugo work?

Accepted Answer

Mechanism of Action

Yeztugo belongs to a class of medications called capsid inhibitors. It works differently than many other HIV treatments by targeting the HIV-1 capsid, which is the protein shell that surrounds and protects the virus's genetic material and the enzymes it needs to multiply.

The medication interferes with the viral life cycle at several distinct stages:

Nuclear Entry: It prevents the virus from transporting its genetic material into the nucleus of the host cell, a step required for the virus to integrate into the cell's DNA.
Virus Assembly: It disrupts the process of building new virus particles inside the infected cell.
Capsid Maturation: It interferes with the formation of the capsid shell in new viruses, resulting in virus particles that are defective and unable to infect other cells.

By blocking these multiple steps, Yeztugo helps lower the amount of HIV in the blood, known as the viral load. Because it uses a unique mechanism to attack the virus, it is particularly useful for individuals whose HIV has developed resistance to other classes of antiretroviral drugs.

Question 4

What are the active ingredients in Yeztugo?

Accepted Answer

The active ingredient in Yeztugo is lenacapavir.

Question 5

What are the side effects of Yeztugo?

Accepted Answer

Common Side Effects

The most frequently reported side effects of Yeztugo involve reactions where the medication is injected. These symptoms are usually mild to moderate but can last for an extended period. Common side effects include:

Injection site reactions: Pain, redness, swelling, itching, or a burning sensation at the site of the injection.
Nodules and induration: Small lumps or hardened areas under the skin at the injection site. These lumps are common and may remain visible or felt for several months.
Nausea: Feeling sick to the stomach.

Serious Side Effects

In some cases, Yeztugo can cause more severe reactions. You should contact your healthcare provider immediately if you experience any of the following:

Severe injection site reactions: Signs of a skin infection, such as pus, drainage, extreme warmth, or ulcers at the site where the medicine was given.
Allergic reactions: Symptoms such as a severe skin rash, hives, swelling of the face, lips, or tongue, or difficulty breathing.
Immune system changes: A condition called Immune Reconstitution Inflammatory Syndrome (IRIS) can occur, where the immune system reacts strongly to previously hidden infections. This is more common in individuals with a history of advanced HIV infection.

This is not a complete list of all possible side effects. If you notice other symptoms or if your injection site reactions become bothersome or do not improve, consult your doctor or pharmacist.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Yeztugo?

Accepted Answer

Yeztugo belongs to the CGRP antagonist drug class.

Question 7

What is the dosage of Yeztugo and how do I take it?

Accepted Answer

How Yeztugo is Administered

Yeztugo treatment typically begins with a starting phase that includes oral tablets. These tablets are taken by mouth, with or without food, for a short period as directed by a healthcare provider.

Following the initial oral doses, the medication is transitioned to long-acting injections. These injections are administered by a healthcare professional under the skin, usually in the abdomen.

Maintenance Schedule

Once the maintenance phase begins, Yeztugo is usually given as an injection once every six months. It is important to attend all scheduled appointments to ensure the medication remains effective.

Missed Doses

If you miss an appointment for an injection or forget to take the oral tablets during the starting phase, contact your healthcare provider right away for guidance. Consistent dosing is necessary to maintain the effectiveness of the treatment.

Question 8

Is Yeztugo safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There is currently not enough research to determine if Yeztugo is safe to use during pregnancy. It is unknown whether the medication can cause harm to a developing fetus. If you are pregnant or planning to become pregnant, your healthcare provider will help you weigh the benefits of the medication against any potential risks.

Breastfeeding

It is not known if Yeztugo passes into breast milk or if it could affect a nursing child. For individuals with HIV, the standard recommendation is to avoid breastfeeding to prevent transmitting the virus to the infant. If you are taking Yeztugo for HIV prevention, talk to your doctor about whether it is safe to breastfeed while receiving this treatment.

Question 9

What forms and strengths does Yeztugo come in?

Accepted Answer

Yeztugo is supplied as a sterile, preservative-free solution for injection. It is available in the following delivery formats:

Subcutaneous Injection: This form is provided in single-dose pre-filled syringes for injection under the skin.
Intravenous Infusion: This form is provided in single-dose vials for administration into a vein by a healthcare professional.

The dosage and administration method are determined by a healthcare provider based on the patient's weight and the condition being treated.

Question 10

What is the FDA approval status of Yeztugo?

Accepted Answer

FDA Approval Status

The U.S. Food and Drug Administration (FDA) approved Yeztugo (emtricitabine and tenofovir alafenamide) on September 23, 2024. It is the first generic version of Descovy to receive FDA approval.

Approved Indications

Yeztugo is approved for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg (77 lbs). It is intended for individuals who are at risk of HIV and have a confirmed negative HIV-1 test result immediately prior to starting the medication.

Boxed Warnings

The FDA-approved labeling for Yeztugo includes a boxed warning, the most serious type of warning, for the following risks:

HIV-1 Resistance: Yeztugo must only be used by individuals confirmed to be HIV-negative. If the medication is taken by someone with an undiagnosed HIV-1 infection, it may lead to the development of drug-resistant HIV-1 strains, making the infection harder to treat.
Hepatitis B Exacerbation: Severe, acute flare-ups of hepatitis B virus (HBV) infection have been reported in patients who have both HIV-1 and HBV and stop taking medications containing emtricitabine or tenofovir. Patients with HBV should be closely monitored by a healthcare provider for several months after stopping Yeztugo.

Regulatory Requirements

To ensure safety and effectiveness, the FDA requires that healthcare providers verify an individual's HIV-negative status before prescribing Yeztugo and at least every three months during treatment. This frequent testing is necessary to prevent the use of PrEP in someone who has acquired HIV-1, which could lead to drug resistance.

Question 11

What should I know about Yeztugo and cost?

Accepted Answer

Factors Affecting Cost

The total cost of Yeztugo can vary based on several factors, including your specific insurance plan and the pharmacy you use. Because this medication is an injection administered by a healthcare professional, there may also be costs associated with the clinic visit and the administration procedure.

Initial vs.

Maintenance Costs

The cost for the first year of treatment is typically higher than in following years. This is because the starting phase requires both oral tablets and injections to reach effective levels in the body. Subsequent maintenance years involve only two injections per year.

Financial Assistance

Patients may be able to lower their out-of-pocket expenses through various programs:

Manufacturer Support: The drug manufacturer may offer copay cards or savings programs for those with commercial insurance to help reduce out-of-pocket costs.
Patient Assistance Programs: Programs may be available for individuals who are uninsured or meet specific income requirements.
Insurance Coverage: Most private insurance plans, Medicare, and Medicaid may cover Yeztugo, but the specific copay or coinsurance amount will depend on the individual plan.

Yeztugo

📋Overview

How It Works

Uses

Active Ingredients

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Yeztugo

Hospitals.net Disclosure